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Loss of midbrain dopaminergic (mDA) neurons and their axons is central to
Parkinson’s disease (PD). Growth differentiation factor (GDF)5 is a potential neu-
rotrophic factor for PD therapy. However, the molecular mediators of its neuro-
trophic action are unknown. Our proteomics analysis shows that GDF5 increases
the expression of serine threonine receptor-associated protein kinase (STRAP)
and nucleoside diphosphate kinase (NME)1 in the SH-SY5Y neuronal cell line.
GDF5 overexpression increased NME1 expression in adult rat brain in vivo.
NME and STRAP mRNAs are expressed in developing and adult rodent midbrain.
Expression of both STRAP and NME1 is necessary and sufficient for the promo-
tion of neurite growth in SH-SY5Y cells by GDF5. NME1 treatment increased neu-
rite growth in both SH-SY5Y cells and culturedmDAneurons. Expression patterns
of NME and STRAP are altered in PDmidbrain. NME1 and STRAP are thus keyme-
diators of GDF5’s neurotrophic effects, rationalizing their future study as thera-
peutic targets for PD.
INTRODUCTION
Parkinson’s disease (PD) is the secondmost common neurodegenerative disorder, affecting 1% of the pop-
ulation older than 60 years (Lees et al., 2009; Tysnes and Storstein, 2017). The neuropathological hallmarks
of PD include the progressive degeneration of midbrain dopaminergic (mDA) neurons and their axons that
project to the striatum via the nigrostriatal pathway (Burke and O’Malley, 2013; Caminiti et al., 2017;
O’Keeffe and Sullivan, 2018). The application of neurotrophic factors to halt and potentially reverse the
degeneration of the nigrostriatal pathway holds significant promise as a disease-modifying therapy for
PD (Kelly et al., 2015; Sullivan andO’Keeffe, 2016). However, despite promising results in open-label clinical
trials (Gill et al., 2003; Slevin et al., 2007; Marks et al., 2008), subsequent randomized double-blind trials of
the dopaminergic neurotrophic factors, glial cell line-derived neurotrophic factor (GDNF) and neurturin,
failed to meet their primary endpoints (Lang et al., 2006; Marks et al., 2010; Warren Olanow et al., 2015;
Whone et al., 2019). This has been suggested to be due to the downregulation of Ret, the common co-re-
ceptor for GDNF and neurturin, by alpha-synuclein (Decressac et al., 2012), a protein that is present in ag-
gregates, called Lewy bodies, in the PD brain. Additional studies have shown that there is an absolute
requirement for Ret for the neurotrophic effect of GDNF on mDA neurons in vivo (Drinkut et al., 2016). It
is therefore important to characterize the effects of other factors that have neurotrophic effects on mDA
neurons, and to decipher the molecular mechanisms that underlie their beneficial effects on this neuronal
population.
One such neurotrophic factor is GDF5, a member of the transforming growth factor (TGF)-b superfamily,
which was originally identified through its key role in limb development in mice and humans (Krieglstein
and Unsicker, 1995; Storm et al., 1994; Storm and Kingsley, 1996). As a member of the TGF-b superfamily,
GDF5 is a distant relative of GDNF and has been demonstrated to have similar neuroprotective effects to
those of GDNF on mDA neurons in vitro (Jaumotte and Zigmond, 2014) and in vivo (Sullivan et al., 1998).
The neurotrophic and neuroprotective effects of GDF5 have been extensively studied in in vivo animal
models of PD (Sullivan et al., 1997; 1998; Costello et al., 2012; Hurley et al., 2004). In addition, GDF5 has
been shown to promote neurite growth in cultured rat dopaminergic (O’Keeffe et al., 2004a, 2004b; He-
garty et al., 2014) and sympathetic neurons (O’Keeffe et al., 2016), and in the SH-SY5Y humaniScience 23, 101457, September 25, 2020 ª 2020 The Author(s).





Articleneuroblastoma cell line (Hegarty et al., 2013), which are widely used in vitro models of PD. GDF5 has also
been reported to enhance neurite complexity, in a hairy enhancer of split (HES)5-dependent manner, in
cultured rat hippocampal pyramidal neurons (Osorio et al., 2013).
The neurotrophic effects of GDF5 are exerted through the canonical bone morphogenetic protein (BMP)
pathway, which involves signaling through a complex of its two receptors, BMPR1B and BMPR2, resulting in
phosphorylation and activation of R-Smad transcription factors, Smad1, Smad5, and Smad9 (Hegarty et al.,
2013; Liu et al., 2016). These Smads subsequently form a transcription factor complex with Smad4, which
translocates to the nucleus and transcribes target genes (Makkar et al., 2009). This pathway has been shown
to mediate the effects of GDF5 in SH-SY5Y cells (Hegarty et al., 2013), cultured rat mDA neurons (Hegarty
et al., 2014), and cultured rat sympathetic neurons (O’Keeffe et al., 2016). Silencing of Zinc finger E-box-
binding homeobox (ZEB) 2, an inhibitor of the BMP-Smad pathway, resulted in enhanced striatal dopami-
nergic innervation in cultured rat mDA neurons; furthermore, Zeb2-deficient mice display dopaminergic
hyperinnervation of the striatum (Hegarty et al., 2017). This role for the BMP-Smad pathway in striatal dopa-
minergic innervation is of interest because nigrostriatal axonal degeneration is a key early pathological
process in PD (for reviews see Burke and O’Malley, 2013; O’Keeffe and Sullivan, 2018). The fact that
GDF5 can exert neurotrophic actions through this Ret-independent pathway is important, given the failure
of the Ret-dependent factors, GDNF and neurturin, in clinical trials (Lang et al., 2006; Marks et al., 2010;
Warren Olanow et al., 2015; Paul and Sullivan, 2018; Whone et al., 2019). The Ret receptor is thought to
be downregulated by alpha-synuclein, which accumulates in the PD brain (Decressac et al., 2012); thus
there is a drive to identify and test alternative dopaminergic neurotrophic factors that are not dependent
on Ret for signaling. Ret-independent factors that act via receptors and signaling molecules that are not
affected by the neuropathology of PD have potential as therapeutic agents.
GDF5 and its receptors are expressed in a temporally and spatially regulated manner in the pre- and post-
natal developing embryonic mouse brain, suggesting that GDF5 plays a role in brain development
(O’Keeffe et al., 2004b; Hegarty et al., 2014). The expression profiles of GDF5 and GDNF and their recep-
tors differ in hydroxydopamine (6-OHDA) lesion in in vivo models of PD. In both striatal and medial fore-
brain bundle (MFB) lesion models, striatal levels of GDF5 mRNA were increased at 10 days post-lesion,
whereas GDNF mRNA levels in the nigrostriatal system were decreased after 10 and 28 days (Gavin
et al., 2014). Expression of GDF5’s receptors, BMPR1B and BMPR2, was unperturbed in both striatal and
MFB-lesioned rats, whereas mRNA levels of the GDNF receptors, Ret and GFR1a, were significantly
decreased (Gavin et al., 2014).
Although the protective effects of GDF5 on dopaminergic neurons have been validated in vitro and in vivo,
and the receptors and some of the signaling pathways are known, there is a need for further information
regarding the molecular pathways that mediate the effects of GDF5 on mDA neurons, to facilitate the
development of targeted therapeutic approaches for PD. To address this, we used the SH-SY5Y cell line
to study the effects of GDF5 on the proteome. We initially used SH-SY5Y cells rather than primary dopami-
nergic neuronal cultures for the proteomics screen, to have a more homogeneous population of cells for
analysis. SH-SY5Y cells are widely used in cell biological studies as an in vitromodel of relevance to PD (Xi-
coy et al., 2017). Furthermore, GDF5 has similar neurotrophic effects on, and acts via the same pathway in,
SH-SY5Y cells as it does in cultured rat mDA neurons (Hegarty et al., 2013, 2014), meaning that this cell line
can be used to screen for molecular mechanisms of relevance to mDA neurons.RESULTS
GDF5 Activates Smad Signaling and Induces a Transcriptional Response in SH-SY5Y Cells
We first confirmed that GDF5 treatment of SH-SY5Y cells activated the canonical BMP-Smad signaling
pathway. To do this, SH-SY5Y cells were plated for 24 h before they were treated with 100 ng/mL recom-
binant human GDF5 for 30, 60, or 120 min. Western blotting revealed a significant increase in the levels of
phospho (p)-Smad1/5/9, which peaked at 30 min after treatment (Figures 1A and 1B). We next validated
these findings by treating SH-SY5Y cells with GDF5 for 30 min and immunocytochemically staining them
for p-Smad1/5/9 and counterstaining with GAPDH and DAPI (Figure 1C). Quantification of the relative nu-
clear fluorescence intensity revealed a significant increase in the levels of p-Smad1/5/9 after GDF5 treat-
ment (Figure 1D). Finally, to confirm that GDF5-induced increases in p-Smad1/5/9 translated to a transcrip-
tional response, we examined the expression of transcripts for the Hes5 and Zeb2, which are known
downstream targets of the BMP-Smad pathway. Real-time PCR confirmed that a 240-min treatment with2 iScience 23, 101457, September 25, 2020
Figure 1. GDF5 Activates Smad Signaling and Induces a Transcriptional Response in SH-SY5Y Cells
(A and B) (A) Representative western blots and (B) densitometry showing the relative level of phospho(p)-Smad1/5/9
staining, normalized to that of Smad1/5/9, in SH-SY5Y cells treated with 100 ng/mL GDF5 for 30, 60, or 120 min. Data are
mean G SEM from three independent experiments (n = 3) (*p < 0.05, **p < 0.01 versus control; one-way ANOVA with
Tukey post-hoc test).
(C–F) (C) Representative images of p-Smad1/5/9 (green), GAPDH (red), and DAPI (blue) staining and (D) graph showing
the relative level of p-Smad1/5/9 staining normalized to that of GAPDH in SH-SY5Y cells treated with 100 ng/mL GDF5 for
30 min. Real-time PCR data showing the relative expression of transcripts for (E) Hes5 and (F) Zeb2 mRNA normalized to
GAPDH mRNA in SH-SY5Y cells treated with 100 ng/mL GDF5 for 4 h. Data are shown as mean G SEM from three




Article100 ng/mLGDF5 led to a significant increase in the expression ofHes5 and Zeb2mRNA (Figures 1E and 1F).
Collectively, these data show that GDF5 activates canonical BMP-Smad signaling in SH-SY5Y cells, making
them a suitable model for a proteomics screen to identify novel mediators of the effects of GDF5.GDF5-Induced Changes in the Proteome in SH-SY5Y Cells and Gene Co-expression Analysis
Using Data from the Human Substantia Nigra (SN) Identifies Correlated Patterns of STRAP
and NME1 Expression
To identify novel regulators of the neurotrophic effects of GDF5, we carried out an untargeted proteomics
analysis of human SH-SY5Y cells treated with GDF5 (Figure 2A). SH-SY5Y cells were treated with 100 ng/mL
GDF5 for 240 min. Total proteins were then extracted from cell lysates and analyzed using liquid chroma-
tography-tandemmass spectrometry (LC-MS/MS). The resulting peptides were identified using MaxQuant
(version 1.6.0.16). A false discovery rate (FDR) of 1% was used to identify unique peptides mapping to a pro-
tein. The resulting label-free quantification (LFQ) values were used to calculate the fold change and p
values. The -log10p value and the log2Fold change were calculated and plotted in a volcano plot using
R-package enhanced volcano from Bioconductor. The resulting volcano plot identified 10 proteins with
a fold change R1.3 and a p value %0.05, and identified 5 proteins with a fold change %0.7 and a p value
% 0.05 (Figure 2B). We then examined this list of differentially expressed proteins for those that might be
candidates to regulate BMP-Smad signaling. Among this list was a protein called serine-threonine kinase
receptor protein (STRAP; UniProtKB Q9Y3F4). This protein was selected for further study as the BMPRs are
serine-threonine kinase receptors, and STRAP has been shown to negatively regulate TGF-b signaling and
to positively regulate protein 3-phosphoinositide-dependent protein kinase-1 (PDPK1) kinase activity by
directly binding to it (Seong et al., 2005). We next identified proteins that were associated with STRAPiScience 23, 101457, September 25, 2020 3
Figure 2. GDF5-Induced Changes in the Proteome in SH-SY5Y Cells and Gene Co-expression Analysis of Data
from the Human SN Identifies Correlated Patterns of STRAP and NME1 Expression
(A) Schema showing the experimental workflow using to identify changes in the proteome induced by GDF5 in SH-SY5Y
cells.
(B) Volcano plots of the -log10p values and the log2Fold change of proteins that were altered in SH-SY5Y cells following
treatment with 100 ng/mL GDF5 for 240 min.
(C–E) (C) Table showing the co-expression scores for genes associated with STRAP in STRING with a medium confidence
threshold, which identified NME1 (highlighted in red), which was also found in the proteomic analyses. Graphs showing
the LFQ intensities from the proteomics screen at 240 min for (D) STRAP and (E) NME1. Data are meanG SEM from three
independent samples per group (n = 3) (*p < 0.05, ***p < 0.001 versus control; Student’s t test).
(F) Linear regression showing the correlation between STRAP andNME1 in the human SN (n = 101). The r and Bonferroni-
corrected p values are shown on the graph. All transcriptome data are 2log expression values. Raw data was obtained
from the Gene expression Omnibus GSE60863 and analyzed using the R2: Genomics analysis and visualization platform
(https://hgserver1.amc.nl/cgi-bin/r2/main.cgi).
(G) Graph showing NME1 expression in the SN of adult rats that had received AAV-Control (‘‘Cont’’) or AAV-GDF5
(‘‘GDF5’’), as a percentage of that on the contralateral side. Data are meanG SEM from n = 4 rats (*p < 0.05 versus control;
unpaired Student’s t test).
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(H) Representative photomicrograph of NME1 (green) and TH (red) expression in the SN of AAV-Cont and AAV-GDF5




Articleby generating a protein-protein interaction network using STRING (https://string-db.org/) with STRAP as
the hub protein. This analysis identified 29 proteins including PDPK1 (Seong et al., 2005), which confirmed
the sensitivity of the approach. We then screened this list and found among it the protein nucleoside
diphosphate kinase A (NME1; UniProtKB: P15531) (Figure 2C), which was also upregulated by GDF5 (Fig-
ure 2B). We next plotted the LFQ intensities of STRAP andNME1 from the LC-MS/MS proteomics data. This
showed that the expression of STRAP (Figure 2D) and NME1 (Figure 2E) was significantly increased at
240 min after GDF5 treatment. We next used gene co-expression analyses, which is a recently developed
approach for the analysis of cellular function based on correlated patterns of gene expression that reflect
potential functional associations (Eisen et al., 1998; Homouz and Kudlicki, 2013). If STRAP and NME1 have a
functional association in mDA neurons, we would expect them to display a gene co-expression pattern in
the midbrain in vivo. To test this, we used available gene expression data (Gene expression Omnibus:
GSE60863; Ramasamy et al., 2014), to examine whether the expression of NME1 and STRAP had a signif-
icant positive correlation in the human substantia nigra (SN). In agreement with the STRING analysis, we
found that STRAP and NME1 displayed a strong positive correlation in the human SN (r = 0.845; p =
1.7 3 1028) (Figure 2F). Collectively, these data suggest a GDF5-STRAP-NME1 functional association.
We also performed immunohistochemical staining on sections of adult rat brain that had been transduced
with adeno-associated virus (AAV)-control or AAV-GDF5 and found increased levels of NME1 protein in
dopaminergic (tyrosine hydroxylase [TH]-immunopositive) neurons within the SN of rats that had received
AAV-GDF5, compared with controls (Figures 2G and 2H). This confirmed that GDF5 overexpression upre-
gulates NME1 in vivo.Strap and Nme1 Are Expressed in the Developing and Adult Rodent Midbrain
We next sought to determine whether Strap and Nme1 were expressed in the mouse midbrain in vivo. To
do this, we quantified the levels of Strap and Nme1mRNAs in the mouse ventral midbrain (VM) at intervals
throughout the period of initial mDA differentiation, axon growth, and striatal innervation, and in adult-
hood, using quantitative real-time PCR. Strap and Nme1 displayed somewhat similar patterns of expres-
sion throughout development. Post-hoc testing showed that the expression of these mRNAs increased
significantly from E10, and that Strapwasmaximally expressed at E12 (Figure 3A), whereasNme1wasmaxi-
mally expressed at E14 (Figure 3B). The expression levels of bothmRNAs subsequently decreased from this
point in development onward (Figures 3A and 3B). There was also a significant decrease in the expression
of Strap andNme1 from P5 to P90 (Figures 3A and 3B). In situ hybridization data from the AllenMouse Brain
Atlas confirmed the co-localization of Strap (Figure 3C) and Nme1 (Figures 3D and 3F) transcripts with the
expression of the mDA markers, Girk2 and Aldh1a1 (Figures 3E and 3G), in adult mouse substantia nigra
pars compacta (SNpc). To verify that these proteins are co-expressed in adult rat SN, we performed immu-
nohistochemical staining, which showed that NME1 was expressed in adult rat SN, in all TH-immunopos-
itive neurons (Figure 3H). This confirms the expression of NME1 in adult mDA neurons.Gene Co-expression Analysis of Human SN Identifies STRAP and NME1 Co-expression with
Multiple Markers of Midbrain Dopaminergic Neurons
Building on the analyses of the mouse brain, we next investigated whether STRAP and NME1 were co-ex-
pressed with multiple markers of mDA neurons in the human SN. To investigate this, we again used avail-
able gene expression data from the Gene expression Omnibus (GSE60863) to determine if STRAP and
NME1 displayed any significant positive correlation with the expression of three markers of mDA neurons:
TH,G-protein-regulated inward rectifier potassium channel (GIRK) 2, and aldehyde dehydrogenase (ALDH)
1A1. Both STRAP and NME1 were found to have a significant positive correlation with all three mDA
markers. These data show that transcripts for STRAP (Figure 4A) and NME1 (Figure 4B) display a positive
co-expression pattern with transcripts for multiple markers of mDA neurons in the human SN, suggesting
that they may play a functional role in mDA neurons. To gain some insight into this, we next identified all
genes that had a significant positive correlation with transcripts for STRAP andNME1 in the human SN (Fig-
ure 4C). A gene ontology (GO) enrichment analysis revealed that the GO category ‘‘Neurofilament cyto-
skeletal organisation’’ (Figure 4C) was among the top two GO categories overrepresented in the lists of
genes that displayed a co-expression pattern with STRAP andNME1. As ‘‘Neurofilament cytoskeletal orga-
nisation’’ was the common ontology of both STRAP and NME1, we examined the co-expression of NME1iScience 23, 101457, September 25, 2020 5
Figure 3. Strap and Nme1 Are Expressed in the Developing and Adult Rodent Midbrain
(A–G) RT-qPCR showing the expression of transcripts for (A) Strap and (B) Nme1 in mouse midbrain from embryonic day
(E) 10 to postnatal day (P) 90 (adult) relative to the levels of the geometric mean of three reference mRNAs, Gapdh, Sdha,
and Hprt1. Data are meanG SEM from n = 4 mice at each time point. (*p < 0.05, **p < 0.01, ***p < 0.01 as indicated; one-
way ANOVA with post-hoc Fisher’s least significant difference (LSD) test, comparing each time point to the one
immediately before and after it). Images of sagittal sections of the P56 mouse brain showing the expression of transcripts
for (C) Strap and (D)Nme1 compared with that of (E)Girk2. Images of coronal sections of the P56mouse brain showing the
expression of (F) Nme1 in the (G) Aldh1a1 domain. The dashed lines indicate the SNpc. Image credit: Allen Institute.





Articleand STRAP with all genes annotated for this ontology in the human SN. The results showed significant pos-
itive correlation between the expression of NME1 and STRAP with Internexin neuronal intermediate fila-
ment protein alpha (INA), Neurofilament heavy (NEFH), ATPase phospholipid transporting 8A2
(ATP8A2), Neurofilament light (NEFL), superoxide dismutase 1(SOD1), and NudE neurodevelopment pro-
tein 1 like 1(NEDL1) (Table 1). Collectively, these data show that STRAP and NME1 are expressed in the
mouse and human SN, and suggest that STRAP andNME1may regulate neurite growth and/or the neurite
growth-promoting effects of GDF5.
STRAP and NME1 Are Necessary for Basal and GDF-5-Induced Neurite Growth in SH-SY5Y
Cells
To test the above-mentioned hypothesis, we next used neurite outgrowth as a phenotypic readout to
examine the effect of small interfering RNAs (siRNAs) against STRAP and NME1 in individual cells. To do
this, we transfected SH-SY5Y cells with 25 nM of a scrambled siRNA (siSCR) or siRNAs targeting STRAP (si-
STRAP) or NME1 (siNME1) together with a GFP expression plasmid to identify transfected cells, which led
to a significant reduction in cellular NME1 expression (Figure 5A). Following transfection, the cells were
cultured with or without 100 ng/mL GDF5 and neurite growth was analyzed at 72 h. Transfection with6 iScience 23, 101457, September 25, 2020
Figure 4. Gene Co-expression Analysis of Human SN Identifies STRAP and NME1 Co-expression with Multiple
Markers of Midbrain Dopaminergic Neurons
(A and B) Linear regression showing the correlation between (A) STRAP and (B) NME1 and three markers of midbrain
dopaminergic neurons (TH, GIRK2, ALDH1A1) in the human SN (n = 101). The r and Bonferroni-corrected p values are
shown on each graph. Raw data were derived from dataset GSE60863 from the Gene Expression Omnibus and analyzed
using the R2 microarray platform.
(C) Table showing the number of genes in the human SN displaying a multiple testing-adjusted correlation of R0.7 with
STRAP (n = 948) and NME1 (n = 1,586), along with a GO enrichment analysis of these gene lists. The top two GO





ArticlesiSTRAP led to a significant reduction in neurite growth compared with siSCR control (51.5% G 6.5% of the
siSCR control) (Figure 5B). GDF5 treatment led to a significant increase in neurite growth in cells transfected
with the siSCR (p < 0.001; 135.1% G 6.7% of the control) (Figure 5B). In contrast, neurite growth in cells
transfected with siSTRAP and cultured with GDF5 was significantly reduced compared with siSCR alone
(p < 0.01), and siSTRAP completely prevented the neurite growth-promoting effects of GDF5 (siSTRAP:
51.5% G 6.5% versus siSTRAP + GDF5: 50.7% G 8.5%) (Figure 5B). Similarly, transfection with siNME1
led to a significant reduction in neurite growth compared with siSCR control (59.5% G 1.3% compared
with the siSCR control) (Figure 5C). Treatment with GDF5 led to a significant increase in neurite growth
in cells transfected with the siSCR (p < 0.01; 135.1% G 6.7% of the control). In contrast, neurite growth
in cells transfected with siNME1 and cultured with GDF5 was significantly reduced comparedwith the siSCR
group, and siNME1 completely prevented the effects of GDF5 on neurite growth (siNME1: 59.5% G 1.3%
versus siNME1 + GDF5: 62.1% G 7.9%) (Figure 5C).Overexpression of STRAP or NME1 Is Sufficient to Promote Neurite Growth in SH-SY5Y Cells
Given that siRNA targeting NME1 or STRAP reduced neurite growth, we next examined whether NME1 and
STRAP overexpression could promote neurite growth. To do this, we transfected SH-SY5Y cells with plas-
mids overexpressing Myc-tagged NME1 or STRAP, while a GFP-expressing plasmid was used as a control.
This resulted in significant overexpression of NME1 protein (Figure 6A). Following transfection, the cells
were cultured with or without 100 ng/mL GDF5 and neurite growth was analyzed at 36 h post-transfection.
NME1 overexpression led to a significant increase in neurite growth at 36 h (218.5% G 11.5% versusiScience 23, 101457, September 25, 2020 7










p = 5.12 3 1032
r = 0.719
p = 2.12 3 1013
ENSG00000100285 NEFH Neurofilament heavy r = 0.862
p = 4.39 3 1027
r = 0.798
p = 1.47 3 1019
ENSG00000132932 ATP8A2 ATPase phospholipid
transporting 8A2
r = 0.872
p = 1.54 3 1028
r = 0.760
p = 2.68 3 1016
ENSG00000277586 NEFL Neurofilament light r = 0.890
p = 1.60 3 1031
r = 0.740




p = 1.53 3 1035
r = 0.850
p = 2.32 3 1025
ENSG00000166579 NDEL1 NudE
neurodevelopment
protein 1 like 1
r = 0.895
p = 1.71 3 1032
r = 0.748
p = 2.21 3 1015
Table 1. List of Genes Annotated for GO:0060052 (Neurofilament Cytoskeletal Organisation) which Are Co-




Articlecontrol), with or without GDF5 (Figure 6B). Similarly, overexpression of STRAP led to a significant increase in
neurite growth (166.7% G 11.1% versus control) with or without GDF5 (Figure 6B). The ability of overex-
pressed NME1 or STRAP to promote neurite growth persisted to 72 h in culture (Figure 6C). Collectively,
these data show that STRAP and NME1 are both necessary and sufficient for basal and GDF5-promoted
neurite growth.Recombinant NME1 Increases Neurite Growth in SHSY5Y Cells and in Cultured E14 Rat mDA
Neurons
Overexpression of NME1 was found to significantly increase neurite length in SH-SY5Y cells. We further
tested whether treatment of SH-SY5Y cells and cultured E14 rat mDA neurons with recombinant human
NME1 would also increase neurite length. Treatment of SH-SH5Y cells for 48 h with 100 or 200 ng/mL re-
combinant NME1 resulted in significant increases in neurite length (Figure 7A), as did treatment for 48 h
of cultured E14 mDA neurons with 100 ng/mL recombinant NME1 (Figures 7B and 7C).Alterations in the Expression of STRAP and NME1 in the PD SN
Finally, we analyzed data from age- and gender-matched samples available in the Gene Expression
Omnibus: GSE49036 (Dijkstra et al., 2015) to examine NME1 and STRAP expression, as well as co-expres-
sion patterns in the SN, of patients with PD at Braak stage 5/6 (n = 8), and of control subjects (n = 8) (Fig-
ure 8A). As expected, there was significant lower expression of the mDA neuron marker ALDH1A1 in PD
samples compared with controls, which validated the approach (Figure 8B). Although there was a trend to-
ward a decrease in STRAP expression in PD samples, this did not reach statistical significance (Figure 8C).
However, there was a statistically significant downregulation of NME1 in the SN of patients with PD
compared with controls (Figure 8D). We also examined the co-expression pattern of STRAP and NME1
with ALDH1A1 in these PD and control SN samples. The rationale for doing this is that in a range of dis-
eases, normal co-expression patterns tend to break down, and these broken correlations can be used as
an index of functional misregulation (Torkamani et al., 2010; Zhang et al., 2013; Southworth et al., 2009).
In agreement with our earlier analyses, we found that both STRAP (r = 0.869, p = 5.07 3 103) (Figure 8E)
and NME1 (r = 0.867, p = 5.31 3 103) (Figure 8G) showed significant positive correlation with ALDH1A1 in
the controls. In contrast, there was no positive correlation of both STRAP (r = 0.500, p = 0.207) and NME1
(r = 0.516, p = 0.191) with ALDH1A1 in PD SN samples (Figures 8F and 8H). These broken correlations sug-
gest a functional misregulation of STRAP-NME1 in PD.8 iScience 23, 101457, September 25, 2020
Figure 5. STRAP and NME1 Are Necessary for Basal and GDF-5-Induced Neurite Growth in SH-SY5Y Cells
(A) Graph and representative photomicrographs showing NME1 expression in SH-SY5Y cells transfected with scrambled
siRNA (siSCR) or NME1 siRNA (siNME1).
(B–D) (B and C) Graphs of neurite length as percentage of control, and (D) representative photomicrographs of SH-SY5Y
cells transfected with siSCR or (B and D) siRNA targeting STRAP (siSTRAP) or (C and D) siNME1 and cultured with or
without 100 ng/mL GDF5 for 72 h. Data are mean G SEM from three independent experiments (n = 3) (**p < 0.01, ***p <






GDF5 is a neurotrophic factor that has been shown to protect mDA neurons from neurotoxic insults in vitro
and in vivo (Sullivan et al., 1997, 1998; Hurley et al., 2004, Toulouse et al., 2012; Costello et al., 2012). In addi-
tion, it is well established that GDF5 promotes neurite growth in SH-SY5Y cells and in cultured rodent mDA
neurons (O’Keeffe et al., 2004a, 2004b; Hegarty et al., 2013, 2014), enhances neurite complexity in cultured
murine hippocampal neurons (Osorio et al., 2013), and increases axonal growth in mouse superior cervical
ganglial cells in vitro (O’Keeffe et al., 2016). The effects of GDF5 on mDA neurons are dependent on
BMPR1B and Smad signaling (Hegarty et al., 2014; Hegarty et al., 2018), whereas the downstream changesiScience 23, 101457, September 25, 2020 9
Figure 6. Overexpression of STRAP or NME1 Is Sufficient to Promote Neurite Growth in SH-SY5Y Cells
(A) Graph and representative photomicrographs showing NME1 expression in SH-SY5Y cells transfected with control or
NME1 expression plasmid.
(B–D) (B and C) Graphs of neurite length as percentages of control and (D) representative photomicrographs of SH-SY5Y
cells transfected with plasmids overexpressing NME1 or STRAP and cultured with or without 100 ng/mL GDF5 for (B) 36 h
or (C) 72 h, as indicated. Data are mean G SEM from three independent experiments (n = 3) (*p < 0.05, **p < 0.01, ***p <
0.001 versus siSCR control or as indicated. n.s. = not significant; two-way ANOVA with post-hoc Fisher’s LSD test or




Articlethat mediate the neurotrophic effects of GDF5 on mDA neurons are unknown. This is important because
GDF5 has been proposed as a candidate neurotrophic factor for therapeutic application in PD (O’Keeffe
et al., 2017; Paul and Sullivan, 2018), where a characteristic feature is axonal degeneration (Burke and
O’Malley, 2013; O’Keeffe and Sullivan, 2018).
In neuronal populations other than mDA neurons, it has been demonstrated that GDF5 can regulate den-
dritic size and complexity through the upregulation and recruitment of HES5 transcription factor (Osorio
et al., 2013). That study also showed that, during development, GDF5 null mice displayed impairments
in dendritic growth from hippocampal pyramidal cells (Osorio et al., 2013). Another study, which examined10 iScience 23, 101457, September 25, 2020
Figure 7. Recombinant NME1 Increases Neurite Growth in SHSY5Y Cells and in Cultured E14 rat mDA Neurons
(A and B) Graphs showing neurite lengths of (A) SHSY5Y cells after treatment for 48 h with 0, 10, 50, 100, or 200 ng/mL
recombinant human NME1 and (B) E14 mDA neurons after treatment for 48 h with 100 ng/mL recombinant human NME1.
(C) Representative photomicrographs of cultured E14 mDA neurons after treatment for 48 h with 0 or 100 ng/mL
recombinant NME1, immunocytochemically stained for TH (green). Data are mean G SEM from three independent





Articlethe role of Dachshund family transcription factor (DACH) 2-histone deacetylase (HDAC) 9 signaling in re-
innervation of muscle endplates, showed that HDAC9 regulates GDF5 expression to enhance motor func-
tioning by promoting innervation in disrupted neuromuscular junctions (Macpherson et al., 2015). In the
present study, in agreement with past work from our group (Hegarty et al., 2013), we show that in the
SH-SY5Y cell line, GDF5 activates the BMP-Smad pathway by phosphorylation of Smad1/5/9 and its subse-
quent nuclear localization. We also found that, similar to the situation in cultured hippocampal neurons
(Osorio et al., 2013), GDF5 treatment results in upregulation of Hes5 and Zeb2 mRNA in SH-SY5Y cells.
We used this model to perform proteomic analysis, investigating the downstream changes in protein
expression that are required for the effects of GDF5 on neurite growth in SH-SY5Y cells. This analysis re-
vealed significant upregulation of two proteins, known as STRAP andNME1, in GDF5-treated cells. Further-
more, we examined the SN from the brains of adult rats that had received intranigral AAV-GDF5 and found
increased levels of NME1 protein compared with controls. This establishes that GDF5-mediated increases
in NME1 protein levels occur not only in SH-SH5Y cells but also are found in the adult rat brain in vivo.
NME1 is a protein that possesses serine/threonine-specific protein kinase activity and plays a role in neural
development; it has been reported to be downregulated in the SN of patients with PD, in a study of genes
related to purine metabolism (Garcia-Esparcia et al., 2015). NME1 is also known to physically interact with
STRAP and to negatively regulate TGFb-mediated signaling (Seong et al., 2007). We used gene co-expres-
sion analysis to show that STRAP and NME1 had a strong co-expression pattern in the human SN, which
suggests a functional association between these two proteins. STRAP was initially isolated from HeLa cells,
as a component of survival of motor neuron complex (SMN) (Meister et al., 2001), and is known to co-
localize with SMN complex components in neurite projections formed in nerve growth factor (NGF)-treated
PC12 cells (Sharma et al., 2005). NME1 has been reported to play several roles in neuronal growth, and it is
known to play a role in fate determination of glial progenitor cells, directing them toward a neuronal fate
(Owlanj et al., 2012). These findings suggest roles for NME1 and STRAP in neuronal growth and develop-
ment. In support of this, we observed a significant increase in the expression of transcripts for STRAP and
NME1 in the mouse VM between E12 and E14, which is the period of maximal axonal outgrowth of mDA
neurons toward their striatal targets. Consistent with this, NME1 is known to be expressed, and to interact
with prune exopolyphosphatase (PRUNE)1, in the midbrain and SN of E14.5 mice (Carotenuto et al., 2006).
We also report that STRAP andNME1 are both expressed in the SNpc of adult mice. Furthermore, we found
that NME1 and TH were co-expressed in mDA neurons in the adult rat SN, further validating our gene co-
expression data. Collectively, these data suggest that STRAP and NME1 play roles in the development and
growth of nigrostriatal dopaminergic neurons.
In our study, the expression of both STRAP and NME1 exhibited strong positive correlation with that of TH,
GIRK2, and ALDH1A1, all of which are markers of mDA neurons. Subsequently, we performed a gene
ontology enrichment analysis of all the genes that are co-expressed with STRAP in the human SN. We
observed that genes that were co-expressed with STRAP were involved in processes such as postsynapticiScience 23, 101457, September 25, 2020 11
Figure 8. Alterations in the Expression of STRAP and NME1 in the PD SN
(A) Schema showing the experimental approach. Raw data were derived from dataset GSE49036, and the R2 microarray platform was used to analyze the
expression and co-expression of STRAP and NME1 in PD.
(B–D) Boxplots showing the log2 expression of (B) ALDH1A1, (C) STRAP, and (D) NME1 in control (Cont) and PD SN samples (*p < 0.05, **p < 0.01 versus
control; Student’s t test).
(E–H) Linear regression analysis showing correlations between (E and F) STRAP and ALDH1A1 and (G and H)NME1 and ALDH1A1 in (E and G) control and (F




Articleintermediate filament cytoskeleton organization and neurofilament cytoskeleton organization. We then
obtained a list of all genes that are co-expressed with NME1 in the human SN and performed a GO analysis
on these. We found that processes that were significantly enriched included circadian sleep/wake cycle and
neurofilament cytoskeleton organization. Further analysis of those genes involved in neurofilament cyto-
skeleton organization in the human SN showed strong correlation between the expression of both
NME1 and STRAO and that of several key proteins that are involved in cytoskeletal processes, namely,
INA, NEFH, ATP8A2, NEFL, SOD1, and NudE NEDL1.
Together, these data suggest that NME1 and STRAP are involved in GDF5-mediated neurite growth. In
agreement with this, we found that silencing of NME1 resulted in impaired neurite growth in SH-SH5Y cells,
a process that is used as a marker of neural differentiation. Furthermore, treatment of SH-SH5Y cells with
GDF5 had no effect on neurite growth when NME1 was silenced. Given these data, we propose that NME1
is an essential downstream effector of GDF5-induced enhancement of neurite growth. Moreover, we found
that NME1 overexpression was sufficient to promote axon growth, and that treatment with recombinant
NME1 protein significantly increased neurite outgrowth in both SH-SY5Y cells and cultured mDA neurons.
In agreement with our data, several other studies have described a role for NME1 in neurite growth, in other
cell types. For example, Wright and colleagues showed that treatment of a collagen substrate with recom-
binant NME1 resulted in increased neurite growth in both chick and rat dorsal root ganglial cell cultures
(Wright et al., 2010). Moreover, it is known that NME1 is secreted and released in cerebrospinal fluid
from patients with traumatic brain injury (Lescuyer et al., 2004) and in neurospheres cultured from mouse
cerebral cortex (Lööv et al., 2013). To our knowledge, ours is the first report of neurite growth-promoting
effects of NME1 in DA neurons. Collectively, our data suggest that GDF5-induced upregulation of NME1 is
involved in the known neurite growth-promoting action of this neurotrophic factor.
We also found that silencing of STRAP impaired basal andGDF5-promoted neurite growth, and that STRAP
overexpression promoted neurite growth in SH-SY5Y cells. To our knowledge, this is the first report of a




Articlelevels are regulated during the differentiation of the human fetal midbrain stem cell line, ReNcell VM (Hof-
frogge et al., 2006); this suggests that regulation of STRAP expression may be associated with cellular dif-
ferentiation. It is well characterized that STRAP inhibits apoptosis by directly interacting with apoptosis
signal-regulating kinase (ASK)1 (Jung et al., 2010). As there is increased apoptosis and axonal degeneration
in the PD brain, GDF5-mediated upregulation of STRAP protein levels in the brain may be involved in the
neuroprotective effects of this factor. Furthermore, it is known that STRAP interacts with TGFb-interacting
protein and that phosphorylation of STRAP at its Ser188 residue by serine/threonine kinase 38 (MPK38) is
important for the pro-apoptotic function of STRAP (Seong et al., 2014). As many kinases are known to play
roles in PD neuropathology, STRAP inhibitionmay provide a new therapeutic approach for slowing the pro-
gression of PD.
Our analysis of datasets of gene expression in PD and control SN found that the expression of NME1 was
significantly lower in the PD brain. In addition, there was a loss of the normal co-expression pattern of
NME1 with the mDA marker, ALDHA1A, in PD patient samples. It has been well-documented that normal
gene co-expression patterns are disrupted in disease states, and that these broken correlations can be
used as an index of functional misregulation (Torkamani et al., 2010; Zhang et al., 2013; Southworth
et al., 2009). NME1 expression has also reported to be downregulated in Alzheimer disease (Cieslak and
Wojtczak, 2018). GDF5-mediated increases in NME1 levels could potentially be applied to address the
loss in NME1 expression, and to restore its co-expression profile inmDA neurons, with the aim of conferring
neuroprotection in PD.
STRAP expression was slightly, although not significantly, reduced in the PD brain, whereas its co-expres-
sion with ALDHA1Awas significantly impaired. Such loss of co-expression in PDmay reflect a role for STRAP
in endogenous protective mechanisms in the brain, which may be adversely affected by PD pathology. It is
known that STRAP has antiapoptotic effects (Jung et al., 2010) and that it can regulate the heat shock pro-
tein (HSP) response by acting as a modulator of p300 (Xu et al., 2008). As HSP signaling is thought to be a
crucial cytoprotective mechanism in PD (Luo et al., 2006), GDF5-mediated upregulation of STRAP might
confer a neuroprotective effect, in addition to its role in increasing neurite growth. This loss of STRAP/ALD-
HA1A co-expression in PD could potentially be rescued by GDF5 treatment, which may be sufficient to
restore levels of STRAP in mDA neurons.
Activation of the BMP-Smad pathway by the GDF5-related factor BMP2 has been found to restore neurite
growth in 1-methyl-4-phenylpyridinium (MPP+)-, 6-OHDA- and a-synuclein-induced in vitro models of PD
(Goulding et al., 2019). Delivery of neurotrophic proteins such as GDF5 and BMP2 to the PD brain is asso-
ciated with issues due to their large size and rapid metabolism, thus strategies aimed at manipulation of
their downstream signaling molecules would be advantageous. The discovery in the present study that
GDF5 treatment induced increases in neurite growth through the regulation of NME1 and STRAP proteins
rationalizes the further study of NME1 and STRAP as potential neuroprotective targets that may be useful
for therapies aimed at axonal regeneration in PD.Limitations of the Study
In our current study, we used SH-SY5Y cells as a model of dopaminergic neurons rather than primary cul-
tures of dopaminergic neurons. This was to ensure a homogeneous population of cells for proteome anal-
ysis, rather than mixed cell cultures of embryonic rat midbrain tissue. Furthermore, SH-SY5Y cells express
several markers of dopaminergic neurons, and are a widely used in vitro model for the study of molecular
signaling of relevance to PD.Resource Availability
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Further information and requests for resources and reagents should be directed to and will be fulfilled by
the Lead Contact, Gerard O’Keeffe (g.okeeffe@ucc.ie).
Materials Availability
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SUPPLEMENTAL INFORMATION.  
TRANSPARENT METHODS 
Cell culture and treatment. SH-SY5Y cells were grown in DMEM-high glucose (D5796) 
supplemented with 10% (v/v) FBS, 1% (v/v) glutamine (G7513), 1% (v/v) non-essential amino 
acids (M7145), 1% (v/v) sodium pyruvate (S8636), and 1% (v/v) penicillin/streptomycin 
(P4333) (all from Sigma). Cells were cultured at 37oC with 5% CO2. For Western blotting and 
RNA extraction, 2.5x106 SH-SY5Y cells were plated overnight on a 6-well plate and treated 
with 100ng/ml of GDF5 (Preprotech; Cat no.120-01) for 0 to 240 min. For analysis of neurite 
length, 30,000-50,000 SH-SY5Y cells were plated overnight on a 24-well plate and treated 
with 100 ng/ml GDF5 for 72h, or with 10, 50, 100 or 200 ng/ml of recombinant human NME1 
(Novus Biological; Cat no. NBP2-252250) for 48 h. Primary cultures of E14 rat VM were 
prepared as described in Hegarty et al., 2014. In brief, E14 embryos were obtained from date-
mated Sprague-Dawley rats under terminal anaesthesia using isoflurane. Dissected VM tissue 
was centrifuged at 1100 rpm for 5 min at 4˚C. The tissue pellet was incubated in 0.1% trypsin-
Hank’s Balanced Salts solution for 5 min at 37˚C with 5% CO2. Following addition of fetal 
calf serum and centrifugation at 1100 rpm for 5 min at 4˚C, the resulting cell pellet was 
resuspended in 1 ml of differentiation media (Dulbecco's modified Eagle's medium/F12, 33 
mM D-glucose, 1% L-glutamine, 1% FCS, supplemented with 2% B27) and triturated. Cells 
were plated on poly-D-lysine (Sigma)-coated 24-well tissue culture plates at a density of 5 x 
104 cells per well in 500 μl of differentiation media at 37˚C with 5% CO2. Cultures were treated 
with 100 ng/ml recombinant human NME1 for 48 h. 
 
 
Western blotting. Cells were lysed in RIPA buffer (10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 0.5 
mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl) 
supplemented with 1 mM sodium orthovanadate, 1mM sodium fluoride and complete protease 
inhibitor cocktail, as per the manufacturer’s recommendation (Roche Molecular Biochemicals; 
11836170001) for 30 min on ice. Lysates were centrifuged at 13,000 rpm for 20 min at 4°C 
and the supernatant was transferred into a fresh tube. The protein concentration of the samples 
was determined using the BCA method (Pierce; Cat no. 23227) and stored at -20°C prior to 
analysis. Upon use, lysates were mixed with a 1x sample loading buffer (SLB) (5xSLB-
containing 70ml glycerol 30ml water with 0.2g of bromophenol blue, 2.5g sodium dodecyl 
sulphate, 0.606g of Tris base with 5-6% v/v β-mercaptoethanol) and boiled at 95oC for 5-10 
min. The samples were then resolved on a SDS-PAGE gel and transferred to a PVDF 
membrane. The membrane was blocked in blocking buffer (containing 5% BSA and 0.1% 
Tween20 in 1xPBS/1xTBS) for 1 h at room temperature, then sequentially probed with primary 
and the appropriate HRP-linked secondary antibodies made up in blocking buffer for 1h at 
room temperature. Enhanced Chemi-Luminescence (ECL) was performed using an ECL kit 
(Thermo Scientific; Cat-32106) following detection and development on an X-ray film for 
optimised durations of exposure in a dark room. The films were then scanned and analysed by 
densitometry using ImageJ software. 
 
Immunocytochemical staining. SH-SY5Y cells were fixed in 4% PFA at 4oC for 20 min at 
room temperature. The cells were then washed with 10mM PBS and permeablized for 30 min 
with 10mM PBS containing 0.01% Triton X-100. The cells were then blocked in 1% BSA 
made in 10mM PBS containing 0.01% Triton X-100 for 1 h at room temperature, and then 
washed in 10mM PBS. Cell were then immunostained with primary antibodies (see below) 
diluted in 1% BSA-PBS containing 0.01% Triton X-100 for 12 h at 4°C, washed with 10mM 
PBS and then probed with secondary antibodies diluted 1% BSA-PBS containing 0.01% Triton 
X-100 for 1 h at room temperature. Nuclei were counter stained using DAPI at a concentration 
of 0.1µg/ml in 10mM PBS for one min. Following washes with 10mM PBS, imaging was 
carried out with an Olympus IX71 inverted microscope fitted with an Olympus DP70 camera 
and the resultant images were analysed using ImageJ software.  
 
Antibodies. The following antibodies were used for Western blotting and immunocytochemical 
staining. Anti-GAPDH (SCBT; SC-47724, 1:1000(WB), 1:200(IF)); Anti-Smad1/5/9 (Abcam; 
ab66737, 1:1000(WB), 1:200(IF)); Anti-p-Smad1/5/9 (CST; 13820, 1:1000(WB), 1:200(IF)). 
HRP-conjugated anti-mouse (ThermoFisher; Cat-A27025) was used at 1:5000 and anti-rabbit 
ThermoFisher; Cat-31460) was used at 1:5000. Alexa Fluor-488 anti-rabbit and Alexa Fluor-
594 anti-mouse conjugated antibodies were used at a concentration of 1:500 (Invitrogen). 
 
qRT-PCR. Cells were removed from the tissue culture dish using a sterile cell scraper and 
centrifuged at 1500 rpm for 5 min at 4oC. Subsequently, the pellets were lysed in 500µl of Tri 
reagent and 250µl Chloroform, vortexed and centrifuged at 13,200 rpm for 10 min. The 
aqueous layer was separated into an Eppendorf tube and 500µl of isopropanol and vortexed 
briefly and centrifuged at 13,200 rpm for 15 min. The supernatant was discarded and the pellets 
were washed with 80% ethanol and re-pelleted by centrifugation at 13,200 rpm for 10 min, 
subsequently air dried for 30 min and dissolved in RNase free water. The RNA yield and purity 
were measured on a Nano drop with nuclease free water as blank. cDNA was synthesized using 
random hexamers. A High capacity cDNA reverse transcription kit (Life Technologies; cat. no 
4368814) was used as per the manufacturers recomendations. The synthesized c-DNA was 
used for real time PCR using the Jump start SYBR green kit (Sigma; cat no. S4438). The 
primers used were as follows Hes5 FW: 5’ CGCATCAACAGCAGCATCGAG 3’ RV: 5’ 
GACGAAGGCTTTGCTGTGCT 3’, Zeb2 FW: 5’ CGACACTCTTGGCGAGGTTT 3’ RV: 
5’ TCACCACTGCGAAGTCTTGTT 3’ and Gapdh FW: 5’ CCACTAGGCGCTCACTGTT 
3’ RV: 5’ ACCAGAGTTAAAAGCAGCCC 3’. RT-PCR was performed on a Real time PCR 
machine by (Life echnologies; cat no. 4376600). The data was then analysed by δδ-Ct method; 
values for individual genes calculated against an endogenous control.  
 
To profile mRNA expression in the developing mouse VM, the levels of Strap and Nme1 
mRNAs were quantified by real-time PCR relative to a geometric mean of mRNAs for the 
house keeping enzymes glyceraldehyde phosphate dehydrogenase (Gapdh), succinate 
dehydrogenase (Sdha) and hypoxanthine phosphoribosyltransferase-1 (Hprt1). Total RNA was 
extracted from dissected VM using the RNeasy lipid mini extraction kit (Qiagen, UK) and 5 μl 
was reverse transcribed for 1 h at 45°C using the AffinityScript kit (Agilent, UK) in a 25 µl 
reaction according to the manufacturer’s instructions. 2 µl of cDNA was amplified in a 20 µl 
reaction volume using Brilliant III ultrafast qPCR master mix reagents (Agilent). PCR products 
were detected using dual-labeled (FAM/BHQ1) hybridization probes specific to each of the 
cDNAs (MWG/Eurofins, Germany). The PCR primers were: Strap forward: 5'-
CGGGTGGAGAAGACTTTA-3' and reverse: 5'-CACAGTTTGCCACAATCTC-3'; Nme1 
forward: 5'-TCTCCCTTCCTATCACCTG-3' and reverse: 5'-CACACATCCTCCACACAA-
3'; Gapdh forward: 5'-GAGAAACCTGCCAAGTATG-3' and reverse: 5'-
GGAGTTGCTGTTGAAGTC-3'; Sdha forward: 5'-GGAACACTCCAAAAACAG-3' and 
reverse: 5'-CCACAGCATCAAATTCAT-3'; Hprt1 forward: 5’-TTAAGCA 
GTACAGCCCCAAAATG-3’ and reverse: 5’-AAGTCTGGCCTG TATCCAACAC-3’. Dual-
labeled probes were: Strap: 5'-FAM-TGTCCCATCTTCAGAACCGCT-BHQ1-3'; Nme1: 5'-
FAM-TCCTGGCACAGTCAGACAACA-BHQ1-3'; Gapdh: 5'-FAM-AGACAACCTG 
GTCCTCAGTGT-BHQ1-3; Sdha: 5′-FAM-CCTGCGGCTTTCACTTCTCT-BHQ1-3', 
Hrpt1: 5’-FAM-TCGAGAGGTCCTTTTCACCAGCAAG-BHQ1-3’. Forward and reverse 
primers were used at a concentration of 150 nM and dual-labeled probes were used at a 
concentration of 300 nM. PCR was performed using the Mx3000P platform (Agilent) using 
the following conditions: 45 cycles of 95°C for 10 s and 60°C for 35 s. Standard curves were 
generated for each cDNA for every real time PCR run, by using serial five-fold dilutions of 
reverse-transcribed mouse adult brain total RNA (Zyagen, USA). Relative mRNA levels were 
quantified in four separate sets of dissected tissues for each age. Primer and probe sequences 
were designed using Beacon Designer software (Premier Biosoft, USA). 
 
Gene Expression Analysis of the Human SN and mouse SN. Human SN gene expression data 
from healthy controls (GSE:60863) (Kang et al., 2011), and from PD and control subjects 
(GSE:49036) (Dijkstra et al., 2015), were analysed using the R2: Genomics Analysis and 
Visualization Platform (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi). Pearson correlation 
analysis with a Bonferroni multiple testing correction was used to identify those genes with a 
significant correlation with STRAP and NME1 expression, and to examine STRAP-NME1 co-
expression. All gene expression data were log2 expression values. Gene ontology (GO) 
enrichment analysis was performed at www.geneontology.org.  
 
Proteomics using label-free LC-MS/MS. SHSY5Y cells were treated with 100 ng/ml GDF5 
for 240 min and lysed in RIPA buffer supplemented with 1 mM sodium orthovanadate, 1mM 
sodium fluoride and complete protease inhibitor cocktail (Roche Molecular Biochemicals) for 
30 min on ice. Lysates were centrifuged at 13,200 rpm for 20 min. Supernatants were resolved 
on an SDS-Page gel and the gel was cut and shipped to Fingerprint Proteomics (University of 
Dundee, UK). Proteins were extracted from the gel, followed by trypsin digestion and passage 
through an Ultima 3000 nano-LC machine for analysis with a flow duration of 2 h. The raw 
data files were then analysed using MaxQuant version 1.6.0.16 carbamidomethylation as a 
fixed modification, all standard contaminants were filtered, 1% FDR was used for peptide 
identification and LFQ intensities were procured, analysis was performed with match between 
runs. From the data procured from MaxQuant, the average LFQ intensities and the fold change 
ratios were calculated. A two tailed Paired Student’s t-test was performed to identify 
significantly upregulated proteins. -Log 10 of P-values and Log2 of fold change were 
calculated and volcano plots were generated using the R-script EnhancedVolcano version 1.4.0 
https://github.com/kevinblighe/EnhancedVolcano) (R version 3.5.3) . 
 
Transfections. SH-SY5Y cells were plated in 24-wells plates and allowed to grow overnight. 
Transfections were performed using TransIT-X2® reagent following the manufacturers 
guidelines. For transfections with DsiRNA, 25nM of siRNA of the following double-stranded 
siRNAs: Scrambled (siSCR) (FW: 5’-CGUUAAUCGCGUAUAAUACGCGUAT-3’: 5’- 
AUACGCGUAUUAUACGCGAUUAACGAC-3’), siNME1 (FW: 5’-
GAGGACUGGUAGAUUACACGAGCT-3’ RV-5’-
AGCUCGUGUAAUCUACCAGUUCCUCAG-3’) and siSTRAP (FW: 5’-
AGGAUAAACUGUUACGCAUAUAUGA-3’ RV-5’-
UCAUAUUGCGUAACAGUUUAUCCUGU-3’). A STRAP-expressing plasmid was 
purchased from Origene (RC209149) and the vector backbone was pCMV6 with a CMV 
promoter, followed by an N-terminal Myc-DDk tag on the STRAP protein. FLAG-NM23-H1 
was a gift from Judy Lieberman (Addgene plasmid #25000; http://n2t.net/addgene:25000; 
RRID: Addgene_25000) and the NME1/NM23 construct had an N-terminal Flag tag followed 
by the NM23 coding sequence in a pCMV4 vector. In all cases, cells were co-transfected with 
an eGFP-expressing plasmid to identify transfected cells. Where indicated, cultures were 
treated with 100 ng/ml GDF5 daily for 72 h.  
 
Neurite length analysis. Transfection and treatments were performed in duplicates as 
described above. Cells were imaged using an Olympus IX71 inverted microscope with the 
CellSense suit. Five images were captured from each well and neurite length was analysed 
using Image J. The averages of all measurements from each independent experiment were 
obtained and used to compare differences in the length of neurites between groups.  
 
Animal Husbandry. Adult female Sprague‐ Dawley rats were procured from Envigo, UK, and 
maintained on a 12h:12h light:dark cycle with access to food and water ad libitum. Rats were 
housed in groups of four in standard housing cages containing environmental enrichment. All 
experiments were conducted fully in accordance with the European Directive 2010/63/EU and 
under an authorisation granted by the Health Products Regulatory Authority Ireland 
(AE19130/P057).  
Virus Preparation and Stereotactic Surgery. AAV2/5-GDF5, AAV2/5-Null and AAV2/6-
Null viral vectors were produced by Vector Biosystems Inc, Philadelphia, USA. In brief, 
AAV2 inverted terminal repeats coding for human GDF5 were packaged using AAV6 or 
AAV5 capsid proteins, to produce AAV2/6 and AAV2/5 viral vectors and the corresponding 
empty control vectors. Transgene expression was driven by synapsin‐ 1 promoter and 
enhanced using woodchuck hepatitis virus post‐ transcriptional regulatory element (WPRE). 
Stereotactic surgery was conducted under general anaesthesia induced by the inhalation agent 
isoflurane. Each animal was placed in a stereotactic frame, an incision was made to the scalp 
and a small hole was drilled into the skull. AAV-Control animals were administered 2 µL 
AAV2/5-Null (1.0×1010 vg/µL) + AAV2/6-Null (5.3×109 vg/µL). AAV-GDF5 animals 
received 2 µL AAV2/5-GDF5 (1.3×1010 vg/µL) + AAV2/6-Null (5.3×109 vg/µL). All vector 
combinations were given unilaterally into the SN at coordinates AP ‐ 5.3, ML ± 2.0, DV ‐ 7.2 
relative to bregma, at an infusion rate of 1µl/min with an additional 2 min for diffusion, before 
withdrawal and suturing. Post-surgery, animals received the analgesic Carprofen (5 mg/kg, 
s.c.) and 5% glucose solution (i.p.) and were allowed to recover fully on a heating-mat before 
being returned to their home cages. 
Tissue Processing. Animals were sacrificed 20 weeks post-surgery by transcardial perfusion-
fixation under terminal pentobarbital anaesthesia (50 mg/kg) for immunohistochemical 
analyses. Brains were post-fixed in 4% paraformaldehyde for 24 h and cryoprotected in 30% 
sucrose solution with 0.1% sodium azide. Sections (30 μm thickness) were cut on a freezing 
stage sledge microtome and were used for immunohistochemistry. 
Immunohistochemical staining. Coronal sections through the SN were mounted onto gelatine-
coated slides and washed for 10 min in tris-buffered saline (TBS) solution. Non-specific 
antibody binding was blocked for 1 h using 3% goat serum diluted in TBS containing 0.02% 
Triton-X100 (TXTBS). Sections were incubated overnight at room temperature with primary 
antibody diluted in TXTBS containing 1% goat serum. Primary antibodies used were: TH 
(Merck Millipore; 1:500) and NME1 (Cell Signaling Technologies; 1:100). Following 3 x 5-
min TBS washes, sections were incubated for 2 h in Alexa Fluor® 594 goat-anti-mouse IgG 
(Invitrogen; 1:200, and Alexa Fluor® 488 goat-anti-rabbit IgG (Invitrogen; 1:200) secondary 
antibodies diluted in TXTBS containing 1% goat serum. Sections were washed for 3 x 5-min 
using TBS and cover-slipped using fluorescent mounting media (Dako Diagnostics). Images 
were taken using the Olympus FV1000 Confocal Laser Scanning Biological Microscope. 
 
Statistical methods. Statistical analyses was performed using GraphPad Prism version 6 
(©2018 GraphPad software, CA USA). Students’s t-test, or one-way or two-way ANOVA with 
post-hoc tests as indicated in the Figure legends, were used as appropriate to identify 
statistically significant differences. All experiments were repeated independently at least three 
times.  
 
 
 
